Venrock Healthcare Capital Partners III, L.P. bought $37.7M of Lycia Therapeutics (LYCA)

Executed Oct 23, disclosed Oct 27, 4 days later.

Value, as filed

$37.7M

2,045,440 sh across 6 lots

Executed

Oct 23

the trade date, as filed

Disclosed

Oct 27

4 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

not yet measured

Not yet measured: the 21-session window has not closed, or the prices around it are not on record.

The filer

VP Venrock Healthcare Capital Partners III, L.P. 10% owner profile →

Venrock Healthcare Capital Partners III, L.P. (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales), most often in KALV. The largest single filing was $37.7M of LYCA (2,045,440 sh across 6 lots, as filed), executed Oct 23. The median gap between execution and disclosure was 4 days.

The name

LYCA

Lycia Therapeutics, Inc. LYCA · Healthcare · 1 filing in 24 months ticker →

Healthcare · Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-cau…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→